Why the study?
Although oxidized LDL is a known cardiovascular risk marker with proatherogenic properties, its in vivo behavior and metabolism, the mechanism of LDL oxidation, and the modified structures of oxidized LDL remain poorly understood.
Answers are grounded in this paper and cite their sources.
Reviews the clinical and pathological features of oxidized low-density lipoprotein (OxLDL) as a risk marker and proatherogenic factor in cardiovascular disease, highlighting remaining gaps in understanding its in vivo oxidation mechanisms and heterogeneous structures.
Oxidized low-density lipoprotein (OxLDL) is a well-known risk marker for cardiovascular diseases. OxLDL has shown a variety of proatherogenic properties in experiments performed in vitro. In addition, immunological studies using monoclonal antibodies have revealed the occurrence of OxLDL in vivo in atherosclerotic lesions and patients' plasma specimens. Resent clinical studies have indicated the prospective significance of plasma OxLDL measurements; however, the behavior and metabolism of OxLDL in vivo is poorly understood. The mechanism by which LDL is oxidized is not clear, and the modified structures of OxLDL are not yet fully understood, partly because OxLDL is a mixture of heterogeneously modified particles. Here, I discuss the recent studies on oxidative modifications in OxLDL and its clinical and pathological features.
No takes yet. Share an insight, caveat, or question.
Hiroyuki Itabe (2008) conducted a review in Atherosclerosis and cardiovascular diseases. Oxidized low-density lipoprotein (OxLDL) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: